Viking Therapeutics (VKTX) Enterprise Value (2014 - 2026)

Viking Therapeutics has disclosed Enterprise Value across 13 years of filings, most recently posting -$603.0 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$603.0 million, up 29.22% year-over-year; the trailing twelve-month figure through Mar 2026 was -$603.0 million (up 29.22% YoY), and the FY2025 annual result was -$705.7 million, up 21.81% from the prior year.
• Enterprise Value came in at -$603.0 million for Q1 2026 at Viking Therapeutics, up from -$705.7 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$135.7 million in Q1 2023 to a low of -$963.0 million in Q1 2024.
• The 5-year median for Enterprise Value is -$603.0 million (2026), against an average of -$567.9 million.
• Across the five-year window, Enterprise Value jumped 61.35% in 2023 and tumbled 609.82% in 2024, its largest moves.
• Viking Therapeutics' Enterprise Value stood at -$155.5 million in 2022, then sank by 132.87% to -$362.1 million in 2023, then plunged by 149.29% to -$902.6 million in 2024, then climbed by 21.81% to -$705.7 million in 2025, then rose by 14.56% to -$603.0 million in 2026.
• The last three Enterprise Value figures came in at -$603.0 million (Q1 2026), -$705.7 million (Q4 2025), and -$714.6 million (Q3 2025), per Business Quant data.